Xencor (NASDAQ:XNCR) Shares Cross Below 200-Day Moving Average – What’s Next?

Xencor, Inc. (NASDAQ:XNCR) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $13.44 and traded as low as $11.17. Xencor shares last traded at $12.06, with a volume of 1,087,794 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on XNCR. Wall Street Zen lowered Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 price objective (down from $18.00) on shares of Xencor in a research note on Tuesday, March 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Friday. Finally, Barclays increased their target price on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $24.38.

Xencor Stock Up 6.3%

The firm has a market cap of $884.48 million, a P/E ratio of -9.73 and a beta of 0.95. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12. The business has a 50-day moving average price of $12.02 and a 200-day moving average price of $13.44.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The firm had revenue of $28.24 million during the quarter, compared to the consensus estimate of $29.97 million. During the same period in the previous year, the company posted ($0.62) earnings per share. The firm’s quarterly revenue was down 46.6% on a year-over-year basis. On average, equities analysts forecast that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insider Activity

In other news, VP John R. Desjarlais sold 2,502 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $11.02, for a total value of $27,572.04. Following the completion of the sale, the vice president owned 263,831 shares in the company, valued at approximately $2,907,417.62. The trade was a 0.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bassil I. Dahiyat sold 6,606 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $11.02, for a total transaction of $72,798.12. Following the transaction, the chief executive officer owned 546,316 shares in the company, valued at approximately $6,020,402.32. This represents a 1.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 44,020 shares of company stock worth $499,817. 5.23% of the stock is currently owned by corporate insiders.

Institutional Trading of Xencor

Hedge funds have recently bought and sold shares of the stock. Amalgamated Bank grew its stake in Xencor by 4.8% in the third quarter. Amalgamated Bank now owns 20,846 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 947 shares during the last quarter. ProShare Advisors LLC lifted its position in shares of Xencor by 6.5% during the fourth quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company’s stock valued at $258,000 after buying an additional 1,026 shares during the last quarter. Cerity Partners LLC lifted its position in shares of Xencor by 3.8% during the fourth quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company’s stock valued at $479,000 after buying an additional 1,143 shares during the last quarter. HighVista Strategies LLC boosted its holdings in shares of Xencor by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 1,362 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,449 shares in the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.